GeneOne Life Science, Inc. (KRX:011000)
787.00
+67.00 (9.31%)
Last updated: Apr 16, 2026, 2:23 PM KST
GeneOne Life Science Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1,319 | 1,180 | 9,111 | 13,261 | 22,310 |
Short-Term Investments | 184.7 | 566.19 | 406.6 | 32,342 | 85,094 |
Trading Asset Securities | 231.18 | - | 470.79 | - | - |
Cash & Short-Term Investments | 1,735 | 1,746 | 9,988 | 45,603 | 107,404 |
Cash Growth | -0.67% | -82.52% | -78.10% | -57.54% | 18.65% |
Accounts Receivable | 1,742 | 7,182 | 6,624 | 8,980 | 7,438 |
Other Receivables | 349.04 | 1,050 | 948.44 | 1,598 | 1,975 |
Receivables | 2,663 | 8,310 | 7,652 | 10,659 | 10,091 |
Inventory | 13,422 | 16,511 | 14,897 | 14,864 | 10,688 |
Prepaid Expenses | 629.02 | 1,542 | 1,225 | 1,145 | 706.46 |
Other Current Assets | 988.11 | 525.52 | 811 | 793.08 | 5,744 |
Total Current Assets | 19,437 | 28,635 | 34,573 | 73,063 | 134,633 |
Property, Plant & Equipment | 95,400 | 117,730 | 111,399 | 144,369 | 110,382 |
Long-Term Investments | 15.31 | 18.5 | 50.39 | 147.49 | 437.33 |
Other Intangible Assets | 208.41 | 189.96 | 385.99 | 563.91 | 643.1 |
Long-Term Deferred Tax Assets | 103.42 | 21.71 | 13.28 | 36.42 | 14.24 |
Other Long-Term Assets | 4,043 | 4,739 | 4,586 | 4,687 | 4,735 |
Total Assets | 119,207 | 151,334 | 151,008 | 222,867 | 250,857 |
Accounts Payable | 24,641 | 20,176 | 10,066 | 7,493 | 17,531 |
Accrued Expenses | 3,820 | 4,910 | 1,971 | 2,327 | 1,173 |
Short-Term Debt | 9,201 | 3,377 | 2,405 | 12,246 | 9,754 |
Current Portion of Leases | 1,472 | 2,895 | 2,396 | 1,911 | 1,543 |
Other Current Liabilities | 14,671 | 11,147 | 6,029 | 9,858 | 4,758 |
Total Current Liabilities | 53,806 | 42,506 | 22,867 | 33,836 | 34,759 |
Long-Term Debt | 20,018 | 16,373 | 6,273 | - | - |
Long-Term Leases | 2,266 | 4,480 | 6,085 | 5,509 | 7,103 |
Pension & Post-Retirement Benefits | 122.12 | 24.1 | 2,096 | - | 820.35 |
Long-Term Deferred Tax Liabilities | 29.3 | 154.83 | 323.98 | 457.33 | 144.32 |
Other Long-Term Liabilities | 2,068 | 2,192 | 1,872 | 1,594 | 1,524 |
Total Liabilities | 78,309 | 65,729 | 39,518 | 41,395 | 44,350 |
Common Stock | 85,410 | 80,039 | 78,474 | 77,752 | 77,479 |
Additional Paid-In Capital | 223,175 | 217,579 | 215,555 | 214,299 | 209,871 |
Retained Earnings | -316,836 | -264,848 | -216,231 | -137,155 | -98,241 |
Treasury Stock | -2,955 | -2,955 | -2,955 | -2,955 | -2,955 |
Comprehensive Income & Other | 52,104 | 55,791 | 36,647 | 29,531 | 20,353 |
Shareholders' Equity | 40,898 | 85,605 | 111,489 | 181,471 | 206,507 |
Total Liabilities & Equity | 119,207 | 151,334 | 151,008 | 222,867 | 250,857 |
Total Debt | 32,958 | 27,126 | 17,160 | 19,666 | 18,400 |
Net Cash (Debt) | -31,223 | -25,379 | -7,171 | 25,937 | 89,004 |
Net Cash Growth | - | - | - | -70.86% | 22.34% |
Net Cash Per Share | -378.76 | -319.49 | -92.24 | 334.73 | 1198.84 |
Filing Date Shares Outstanding | 82.33 | 79.83 | 78.26 | 77.54 | 77.27 |
Total Common Shares Outstanding | 82.33 | 79.83 | 78.26 | 77.54 | 77.27 |
Working Capital | -34,369 | -13,870 | 11,705 | 39,227 | 99,875 |
Book Value Per Share | 496.77 | 1072.35 | 1424.52 | 2340.29 | 2672.55 |
Tangible Book Value | 40,690 | 85,415 | 111,103 | 180,907 | 205,864 |
Tangible Book Value Per Share | 494.24 | 1069.97 | 1419.59 | 2333.02 | 2664.23 |
Land | 3,607 | 3,720 | 3,139 | 4,081 | 3,817 |
Buildings | 74,505 | 76,192 | 63,374 | 1,403 | 1,331 |
Machinery | 56,904 | 55,318 | 48,599 | 15,199 | 11,775 |
Construction In Progress | - | - | - | 104,661 | 78,283 |
Leasehold Improvements | 17,230 | 16,414 | 14,867 | 13,139 | 12,124 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.